Fialuridine - BioMed Valley Discoveries

Drug Profile

Fialuridine - BioMed Valley Discoveries

Alternative Names: [124I]FIAU; BVD-INF/DFI; BVD-INF/PJI; rFIAU

Latest Information Update: 18 Jan 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioMed Valley Discoveries
  • Class Imaging agents; Nucleosides; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 01 Aug 2013 BioMed Valley Discoveries terminates a phase II trial for Osteomyelitis (in patients with diabetic foot infections) diagnosis in USA (NCT01764919)
  • 01 Aug 2013 BioMed Valley Discoveries terminates phase-II clinical trials in Bacterial infections (prosthetic joint infections) diagnosis in USA (NCT01705496)
  • 01 Mar 2013 BioMed Valley Discoveries completes phase-I clinical trials in Bacterial infections (prosthetic joint infections) diagnosis in USA (NCT01337466)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top